National Taiwan University Hospital
Taipei, 100, Taiwan
Location status: Recruiting
NCT Number: NCT05413655
This is a phase 2, randomized, double-blind, placebo-controlled study of oral EX039 as add-on to Acetylcholine Esterase Inhibitors in subjects with mild Alzheimer's disease.
Interested in participating?
Request Info50 year–80 year
All sexes
Interventional
Phase 2
Taipei, 100, Taiwan
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
/ intracranial hemorrhage temporally related to the onset of worsening of cognitive impairment) per investigator judgement.
The dosage form of EX039 is the capsule for oral use
The dosage form of Placebo is the capsule for oral use
Time frame: Week 28
Mean change from baseline in Alzheimer's Disease Assessment Scale-cognitive subscale measured at the end of week 28. Total scores range from 0-70, with higher scores (≥ 18) indicating greater cognitive impairment.
Time frame: Week 28
Mean change from baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB). measured at the end of week 28. Total scores range from 0 to 18, with higher scores indicating more worsening.
Time frame: Week 4, 12, 20, 28
Scorings of Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) at the end of week 4, 12, 20, and 28.
Time frame: Week 30
To assess the safety and tolerability of EX039
Time frame: Week 28
The percentage of the recruited subjects whose mean change from baseline in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) measured at the end of week 28 is improved (≧4) without deterioration of CDR-SB and CIBIS-Plus
Contact information is provided by the study sponsor or research team.
Excelsior
Industry
A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Oral EX039 As Add-on to Acetylcholine Esterase Inhibitors in Subjects with Mild Alzheimer's Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06014424
Alzheimer Disease, Brain Diseases
Calgary, Alberta, Canada
View Trial DetailsNCT06847321
Alzheimer Disease, Alzheimer Disease Due to P. Gingivalis
Phoenix, Arizona, United States
View Trial DetailsNCT06937229
Aberrant Motor Behavior in Dementia, Agitation
Chandler, Arizona, United States
View Trial DetailsNCT06862960
Alzheimer Disease, Brain Diseases
Fuzhou, Fujian, China
View Trial Details